The cost-effectiveness of warfarin pharmacogenomics

J Thromb Haemost. 2007 Sep;5(9):1974-5. doi: 10.1111/j.1538-7836.2007.02699.x. Epub 2007 Jul 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anticoagulants / pharmacology*
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Cost-Benefit Analysis*
  • Cytochrome P-450 CYP2C9
  • Humans
  • Mixed Function Oxygenases / genetics
  • Pharmacogenetics / economics*
  • Vitamin K Epoxide Reductases
  • Warfarin / pharmacology*

Substances

  • Anticoagulants
  • Warfarin
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Vitamin K Epoxide Reductases